Claims for Patent: 9,551,033

Summary for Patent: 9,551,033

Title:	Gene expression markers of tumor resistance to HER2 inhibitor treatment
Abstract:	The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
Inventor(s):	Lee-Hoeflich; Si Tuen (Millbrae, CA), Stern; Howard (San Carlos, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	12/806,419
Patent Claims:	1. A method of predicting the likelihood of response of a mammalian subject diagnosed with or at risk of developing a HER2 expressing tumor to treatment with a HER2 inhibitor, comprising (a) measuring in a tumor cell sample obtained from said human subject, an identical or increased expression level of the RNA transcript or expression product of a PPM1H gene relative to the expression level of PPM1H gene in a normal cell of the same cell type, wherein the identical or increased expression level identifies the subject as not likely to be resistant to treatment with trastuzumab, and (b) treating the subject with trastuzumab. 2. The method of claim 1 wherein the tumor is selected from the group consisting of breast cancer, squamous cell cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophagael cancer, tumors of the biliary tract, and head and neck cancer. 3. The method of claim 1 wherein the tumor is selected from the group consisting of carcinomas of the stomach, endometrium, salivary gland, lung, kidney, colon, thyroid, pancreas and bladder, and prostate cancer. 4. The method of claim 1 wherein the tumor is breast cancer. 5. The method of claim 4 wherein the tumor is metastatic breast cancer. 6. The method of claim 1 wherein the tumor cell sample is from a fixed, wax-embedded cancer tissue specimen of said patient. 7. The method of claim 1 wherein the tumor cell sample is a core biopsy tissue. 8. The method of claim 1 wherein said tumor cell sample is from a biological fluid. 9. The method of claim 8 wherein the biological fluid is selected from the group consisting of blood, urine, saliva, ascites fluid, blood serum and blood plasma. 10. The method of claim 1, wherein measurement of the expression level is implemented using an apparatus adapted to determine the expression level of said RNA transcript or said expression products. 11. The method of claim 10, wherein the measurement of the expression levels is performed by using a software program executed by a suitable processor. 12. The method of claim 11, wherein the program is embodied in software stored on a tangible medium. 13. The method of claim 12, wherein the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor. 14. The method of any one of claims 10 to 13, further comprising the step of preparing a report recording the results of said measurement. 15. The method of claim 14, wherein said report is recorded or stored on a tangible medium. 16. The method of claim 15, wherein the tangible medium is paper. 17. The method of claim 15, wherein the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor. 18. The method of any one of claims 10 to 17, further comprising the step of communicating the results of said determination to an interested party. 19. The method of claim 18, wherein the interested party is the patient or the attending physician. 20. The method of claim 18 or claim 19, wherein the communication is in writing, by email, or by telephone.

Details for Patent 9,551,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-06-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-06-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2027-06-08